FDA clears IND application for ERAS-4001 for the treatment of patients with KRAS-mutant (KRASm) solid tumors June 3, 2025
FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib May 27, 2025
Orionis Biosciences and Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer May 27, 2025
First Patient Dosed in TNG456 Ph 1/2 Trial in Patients With MTAP-deleted GBM and Other Solid Tumors May 27, 2025
OSE Immunotherapeutics, Inside Therapeutics, and Angers-based MiNT Laboratory to develop mRNA therapeutics and accelerate nanodrug development May 27, 2025
Helix BioPharma Secures Pre-IND Candidates LEUMUNA™ and GEMCEDA™ in Strategic Acquisition from the Laevoroc Group May 27, 2025
Monotherapy and combo arms of BBI-355 in POTENTIATE trial to be discontinued; BBI-355 – BBI-825 combo to be investigated May 27, 2025
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 In Combination with KEYTRUDA May 21, 2025
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline May 21, 2025
AbbVie and ADARx Pharmaceuticals to Develop Next-Gen siRNA Therapies Across Multiple Therapeutic Areas May 21, 2025
Tempus Enters Multi-Year Strategic Collaboration with Boehringer Ingelheim to Advance its Cancer Pipeline May 21, 2025
IND application for Ph 1 trial of Penetrium™ in combination with docetaxel voluntary withdrawn May 21, 2025
IND cleared for ERAS-0015 and IND submitted for ERAS-4001; Ph 1 monotherapy data for both programs expected in 2026 May 21, 2025
Cellipont Bioservices and Optieum Biotechnologies Partner to Advance cGMP Manufacturing of CAR-T Therapy for Glioblastoma May 13, 2025
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific ADC Program May 6, 2025
